US Patent Issued to JANUX THERAPEUTICS on Oct. 7 for "Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens" (California Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,433,953, issued on Oct. 7, was assigned to JANUX THERAPEUTICS INC. (San Diego).

"Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens" was invented by David Campbell (San Diego), Thomas R. Diraimondo (San Diego) and Ramesh Bhatt (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are multispecific antibodies that selectively bind to EGFR and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same."

The patent was filed on Oct. 17, 2024, under Application No. 18/919,094.

*For further informa...